Shionogi - Dolutegravir Can Bring ‘Good Times’ Back to Shionogi!
Topline data from PhIII SINGLE trial are encouraging and similar outcome from four late stage studies can bring Dolutegravir in forefront of anti-HIV therapy – this is the first drug showing superiority of this extent to current standard of care Atripla (Gilead, FY 11 sales $3.2b); though the competitive landscape is rapidly changing in anti-HIV regime, we expect dolutegravir has potential to cross $2.5b. In this report we have analyzed dolutegravir opportunity in mono-thx and in combination therapy based on data announced and taking the emerging competition into consideration.
COMPANIES MENTIONED
Shionogi
Shionogi
